Fig. 1

Endocan concentrations in patients with COVID-19 at admission and during the hospitalization. a Endocan levels measured at the admission in patients with COVID-19. Data are presented as median and interquartile range. Patients with COVID-19 were compared to the control group using the Mann–Whitney test. *p < 0.05. b Endocan levels measured at the admission in patients with COVID-19 categorized into non-ARDS, mild/moderate ARDS and severe ARDS. Data are presented as median and interquartile range. Results were expressed as mean and standard deviation. Intergroup comparison was made using the Kruskal–Wallis test. *p < 0.05. c Endocan levels measured over the course of hospitalization in patients with COVID-19 and ARDS. Mild/moderate ARDS group n = 10 (days 1–2), n = 3 (days 3–4), n = 3 (days 5–6), n = 2 (days 7–8); severe ARDS group n = 18 (days 1–2), n = 12 (days 3–4), n = 13 (days 5–6), n = 9 (days 7–8). Results are expressed as mean ± standard deviation. Difference in endocan levels over the course of the hospitalization was calculated using the two-way ANOVA followed by Bonferroni’s posttest. **p < 0.01